PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3902 trials with phase data)• Click on a phase to view related trials
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2000
- Registration Number
- NCT07096024
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
- Conditions
- COVID-19
- Interventions
- Drug: nirmatrelvir-ritonavir
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14000
- Registration Number
- NCT07090486
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Conditions
- Advanced/Metastatic Solid TumorsBladder CancerUrothelial CarcinomaAdvanced Non-Small Cell Lung CancerCarcinoma, Non Small Cell LungCarcinoma, Squamous Cell of Head and NeckHead and Neck CancerEsophageal CancerGastroesophageal Junction AdenocarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- Drug: PF-08046876
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 310
- Registration Number
- NCT07090499
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1200
- Registration Number
- NCT07089680
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT07086664
- Locations
- 🇺🇸
Javara - Nevada Health Centers - Carson City, Carson City, Nevada, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 637
- Next
News
Allan Camaisa Joins Res Nova Biologics Advisory Board to Advance Breast Cancer Immunotherapy
Former Calidi Biotherapeutics Chairman and CEO Allan Camaisa has joined Res Nova Biologics' Advisory Board to accelerate development of breast cancer immunotherapies.
Certara Appoints AI Pioneer Dr. Chris Bouton as CTO to Advance Next-Generation Drug Development Platform
Certara has appointed Dr. Christopher Bouton, founder of Vyasa Analytics, as Chief Technology Officer to lead development of an AI-powered model-informed drug development platform.
Basilea Launches Phase 3 Trial for Novel Antifungal Fosmanogepix in Invasive Mold Infections
Basilea Pharmaceutica has initiated FORWARD-IM, a phase 3 registrational study evaluating fosmanogepix for treating invasive mold infections in adults, with completion expected in Q1 2028.
Ivonescimab Demonstrates Superior Efficacy in Phase III Lung Cancer Trials, Positioning for Global Regulatory Approvals
Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.
Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer
A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs
Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.
RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study
RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.